Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company reports the entry into new Change-in-Control Agreements with Named Executive Officers and certain other executives. The agreements became effective on January 1, 2005, replacing expired agreements from December 31, 2004. The filing date is January 1, 2005.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes Versus Prior Period
The primary material change is the renewal of Change-in-Control Agreements. The new agreements are materially similar to the expired agreements but establish a new effective period starting January 1, 2005, with automatic annual renewals unless notice of expiration is given.
Guidance, Outlook, and Material Terms
The filing details the terms of the new executive agreements, which provide severance and benefits upon a "change in control" and subsequent termination within 36 months. Key provisions include:
- Severance Payment: A lump sum equal to three times the sum of the executive's base salary and the greater of the current or preceding year's target annual bonus.
- Equity Acceleration: Immediate vesting and exercisability of all outstanding stock options and lapse of restrictions on restricted stock awards.
- Pension Enhancement: An actuarially equivalent cash lump sum representing the excess of a hypothetical pension (calculated with 36 additional months of service and age) over the currently vested pension.
- Benefits Continuation: Life and health insurance benefits and perquisites for 36 months post-termination, followed by eligibility for retiree medical and dental plans.
- Tax Gross-Up: The company will gross up compensation to offset excise taxes, subject to a "safe harbor" reduction of up to 10% if it avoids the tax.
- Conditions: Executives must sign non-compete/non-solicitation and general release agreements.
Investor Verification Checklist
- Verify the specific list of Named Executive Officers covered under these new agreements.
- Confirm the definition of "Cause" and "Good Reason" within the agreement text to understand termination triggers.
- Review the company's total potential liability exposure for these severance packages in the event of a change in control.
- Check for any subsequent filings regarding the actual execution of these agreements or changes to the executive roster.